|Bid||28.70 x 800|
|Ask||28.70 x 2200|
|Day's Range||27.80 - 28.94|
|52 Week Range||20.10 - 48.40|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.
Wall Street is set for a sleepy open Monday with stock futures indicating modest gains across all three indexes. The Dow Jones Industrial Average, S&P 500 and Nasdaq Compositewere all set to open up 0.1% as of 8:20 a.m. in what is expected to be a quiet day for trading. (AZN) (ticker: AZN) and (MRK) (MRK) were up 0.6% and 0.2%, respectively, after Lynparza, the ovarian-cancer drug they market, won approval by the Food and Drug Administration to be used to treat advanced pancreatic cancer.
Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza. BRACAnalysis CDx is the only FDA-approved genetic test for this indication. Lynparza is marketed by AstraZeneca PLC and Merck & Co. Inc. . "The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments," said Ruth March, head of precision medicine at AstraZeneca. Myriad Genetics's stock has lost 7.9% year to date through Friday, while the S&P 500 has gained 29%.
The Food and Drug Administration approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.
It hasn't been the best quarter for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, since the share price has fallen...
Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
Is Tri Pointe Group Inc (NYSE:TPH) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market […]
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
Shares of Myriad Genetics dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis. Myriad said that Prequel, which uses whole-genome sequencing, can help reduce the need for expensive procedures like amniocentesis or chorionic villus sampling. Sales of its prenatal business, which makes up about 12% of total revenues, rose 5% to $23.5 million in the most recent quarter, up from $18.1 million in the same period a year ago. Myriad's stock has tumbled 14% year-to-date. The S&P 500 is up 24%.
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Myriad Genetics, Inc. (NASDAQ: MYGN) securities between September 2, 2016 to August 13, 2019 (the "Class Period"). Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
Investors who take an interest in Myriad Genetics, Inc. (NASDAQ:MYGN) should definitely note that the Independent...
Shares of Myriad Genetics crashed Tuesday after the genetic-testing company missed fiscal first-quarter estimates and slashed its full-year outlook. It blamed an administrative change.
Shares of Myriad Genetics Inc. plummeted 35% to pace all premarket decliners, after the molecular diagnostics company reported fiscal first-quarter results that were well below expectations and slashed its full-year outlook. The company reported late Monday a net loss for the quarter to Sept. 30 of $20.6 million, or 28 cents a share, after a loss of $700,000, or 1 cent a share, in the year-ago period. Excluding non-recurring items, such as stock-based compensation expenses and acquisition-related charges, adjusted earnings per share came to 8 cents, below the FactSet consensus of 31 cents. Revenue fell 7.9% to $186.3 million, missing the FactSet consensus of $202.3 million. "We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the deletion of the historical hereditary cancer CPT codes," said Chief Executive Mark Capone. The company cut its fiscal 2020 guidance ranges for adjusted EPS to $1.00 to $1.10 from $1.80 to $1.90 and for revenue to $800 million to $810 million from $865 million to $875 million. The stock had gained 21% year to date through Monday, while the S&P 500 has advanced 23%.
STOCKSTOWATCHTODAY BLOG U.S. stock futures were higher Tuesday morning. And third-quarter earnings reports had several companies’ shares moving in premarket trading. Dow Jones Industrial Average futures were up 0.